Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1CNS 1

Conditions

Melanoma 34Neoplasms 21Carcinoma, Non-Small-Cell Lung 7Brain Neoplasms 5Skin Neoplasms 4Neoplasm Metastasis 4Glioma 4Thyroid Carcinoma, Anaplastic 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Glioblastoma 2Ganglioneuroma 2Ganglioglioma 2Colorectal Neoplasms 2Astrocytoma 2Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Nonseminomatous germ cell tumor 1Neurofibromatosis 1 1Multiple Myeloma 1Melanoma, Cutaneous Malignant 1Leukemia, Hairy Cell 1Gastrointestinal Stromal Tumors 1Fever 1

Interventions

AZD 6244 6trametinib 1mirdametinib 1lorlatinib 1encorafenib 1dabrafenib 1binimetinib 1Everolimus 1Dosage Forms 1Cetuximab 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neurofibromatosis 1 × dabrafenib × Clear all
NCT03975829 2026-06-11

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Active not recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡